PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. Centers for Disease Control and Prevention (CDC), and 95.3% Both doses of abrocitinib met the co-primary study endpoints. effective against severe COVID-19 as defined by the FDA.
40 
Let's personalize your content